Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Citations
675 citations
569 citations
444 citations
Cites methods from "Lenalidomide, Bortezomib, and Dexam..."
...The data to support their use from recent randomized trials using new active agents for multiple myeloma are provided in Table 7.(38,39,88,89) In order to initiate therapy, patients must meet criteria for multiple myeloma as outlined in Table 1....
[...]
...A trial by the Intergroupe Francophone du Myelome (IFM) compared early vs delayed ASCT in patients treated with VRd followed by lenalidomide maintenance.(39) Patients were randomized to receive either VRd (three cycles) followed by ASCT and then VRd consolidation (two cycles) vs VRd × eight cycles with ASCT reserved for...
[...]
419 citations
Additional excerpts
...Mean, months (range)§ 30 (0-108) 13 (0-51) 25 (0-61) 25 (0-55) 39 (27-55) 20 (0-49) 35 (2-71) 29 (0-75) 28 (0-108) 22 (0-86)...
[...]
...0) Adverse-risk cytogenetics, t(4;14) or del17pk¶ Yes — — 41 (13....
[...]
359 citations
References
2,650 citations
2,411 citations
2,030 citations
1,728 citations
1,681 citations